產(chǎn)品名稱：ß2-Glycoprotein I Screen ELISA 產(chǎn) 地：Demeditec 產(chǎn)品貨號：DE7270 產(chǎn)品規(guī)格：96 Tests 產(chǎn)品說明： Special remarks: Anti-b2-Glycoprotein I Screen is an indirect solid phase enzyme immunoassay (ELISA) for the semiquantitative screening of IgG, IgM and IgA class autoantibodies against b2-Glycoprotein I in human serum or plasma. The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of an increased risk of thrombosis in patients with Systemic Lupus Erythematosus (SLE) or lupus-like disorders. Anti-b2-Glycoprotein I antibodies are associated with the diseases of the antiphospholipid syndrome, like thrombosis, thrombocytopenia or fetal loss in the context of systemic lupus erythematosus. b2-Glycoprotein I (apolipoprotein H) is a 50 kDa b2-globulin occurring in plasma at a level of 200 µg/ml. It has been found that b2-Glycoprotein I (b2GPI) inhibits the intrinsic coagulation pathway and, therefore, it is involved in the regulation of blood coagulation. b2GPI is associated in vivo with negatively-charged substances, e.g. anionic phospholipids, heparin and lipoproteins. The phospholipid binding region is located on its fifth domain. Recently, b2-Glycoprotein I has become well-known as a co-factor for anti-Cardiolipin auto-antibodies. Several studies confirmed its indispensable role in proper binding of anti-Cardiolipin antibodies to immobilized Cardiolipin. Detailed investigations about the nature of the Cardiolipin-b2GPI-complex have shown that epitopes on the fifth domain of b2GPI are the real target of "anti-Cardiolipin antibodies" - even in the absence of negatively-charged phospholipids. b2GPI is not only a prerequisite for the binding of anti-Cardiolipin antibodies; it has now been identified as the primary antigen for these antibodies. Samples from clinical patients with the antiphospholipid syndrome were tested for anti-Cardiolipin and anti-b2GPI antibodies. Good correlations between the anti-Cardiolipin and anti-b2GPI values confirm the statement above. Autoantibodies against b2-Glycoprotein I are described for various autoimmune diseases. The presence of anti-b2GPI antibodies can be related to the development of arterial and venous thromboses, venous thromboembolism, thrombocytopenia and fetal loss. Anti-b2-Glycoprotein I antibodies are found in the immunoglobulin classes IgG, IgM and IgA. The determination of IgM antibodies is a valuable indicator in the diagnosis of beginning autoimmune diseases, whereas IgG antibodies will be found in progressive stages of mani-fested autoimmune disorders. Anti-b2GPI IgG antibody titers correlate well with the clinical status of the patients in thrombosis, thromboembolism and repeated fetal loss, while anti-b2GPI IgM antibodies show a significant association with thrombosis and thrombocytopenia. Indications for determination of anti-b2-Glycoprotein I antibodies: - SLE - arterial and venous thromboses - venous thromboembolism - thrombocytopenia - fetal loss 上海玉博生物技術(shù)有限公司在為生命科學(xué)領(lǐng)域提供豐富的產(chǎn)品與信息資源方面處于國內(nèi)**地位，公司提供的產(chǎn)品涵蓋了二十多個國家近五十萬種產(chǎn)品，而且產(chǎn)品的數(shù)量與信息在不斷的增長和更新，公司提供的產(chǎn)品能夠使生命科學(xué)工作者加快對生物化學(xué)，分子生物學(xué)，細(xì)胞生物學(xué)以及蛋白質(zhì)組學(xué)研究的認(rèn)知，以及分子診斷和臨床醫(yī)學(xué)領(lǐng)域的應(yīng)用。
滬公網(wǎng)安備 31011002002623號
